Aviko Radiopharmaceuticals

Aviko Radiopharmaceuticals is a private, preclinical-stage biotech company pioneering Boron Neutron Capture Therapy (BNCT) for cancer. Founded and funded by Deerfield Management, the company is developing targeted boron medicines designed to be activated by neutron irradiation, offering a potential precision treatment for solid tumors with high unmet need. Aviko's strategy centers on building a collaborative ecosystem, partnering with biopharma for drug development and with medical centers for clinical delivery, rather than developing neutron sources itself. The company is currently in the research and development phase, building its team and platform with support from Deerfield's integrated drug development capabilities.

Development of novel, tumor-targeting boron-10 carrier drugs for Boron Neutron Capture Therapy (BNCT). The platform focuses on medicinal chemistry and bioconjugation to create agents with high tumor selectivity and boron payload, designed to be activated by external neutron irradiation to destroy cancer cells.

BNCT competition includes companies like Stella Pharma (Japan, acquired by Sosei Heptares) and Neutron Therapeutics (developing neutron sources, a potential partner). More broadly, Aviko competes with other advanced radiotherapy modalities (e.g., proton therapy, flash therapy) and targeted radiopharmaceuticals (e.g., Pluvicto). Its key differentiator is the focused development of next-generation boron pharmaceuticals.